Literature DB >> 21565468

What we know and what we don't know about the treatment of schizoaffective disorder.

A Murru1, I Pacchiarotti, A M A Nivoli, I Grande, F Colom, E Vieta.   

Abstract

Schizoaffective disorder (SAD) is a chronic, severe and disabling illness consisting on the concurrent presentation of symptoms of schizophrenia and affective disorders (depression and/or mania). Evidence for the treatment of SAD mostly derives from studies based on mixed samples (i.e. schizophrenic and schizoaffective patients) or on extrapolations from studies on schizophrenia or bipolar disorder. The objective of the present review is to systematically consider and summarize the best evidence-based approaches to the treatment of SAD and extensively point out the gap between treatment research and clinical practice of this disorder. The complex problem of controlling the pleomorphic presentation of SAD's syndromic construct is reflected in the lack of evidence on key topics, including: diagnostic consistency, pharmacological approaches (mood stabilizers, antidepressants, both in acute and maintenance treatment as well as their possible combination), and the adjunctive role of psychosocial and biophysical interventions. Finally, treatment strategies for SAD, both unipolar and bipolar type, are proposed.
Copyright © 2011 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21565468     DOI: 10.1016/j.euroneuro.2011.03.001

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  9 in total

1.  Symptom changes in five dimensions of the Positive and Negative Syndrome Scale in refractory psychosis.

Authors:  Todd S Woodward; Kwanghee Jung; Geoffrey N Smith; Heungsun Hwang; Alasdair M Barr; Ric M Procyshyn; Sean W Flynn; Mark van der Gaag; William G Honer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-10-15       Impact factor: 5.270

Review 2.  Antipsychotic Management of Schizoaffective Disorder: A Review.

Authors:  Jean-Pierre Lindenmayer; Amandeep Kaur
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

3.  Lower glutamic acid decarboxylase 65-kDa isoform messenger RNA and protein levels in the prefrontal cortex in schizoaffective disorder but not schizophrenia.

Authors:  Jill R Glausier; Sohei Kimoto; Kenneth N Fish; David A Lewis
Journal:  Biol Psychiatry       Date:  2014-05-29       Impact factor: 13.382

4.  Long-Term Real-World Effectiveness of Pharmacotherapies for Schizoaffective Disorder.

Authors:  Jonne Lintunen; Heidi Taipale; Antti Tanskanen; Ellenor Mittendorfer-Rutz; Jari Tiihonen; Markku Lähteenvuo
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 9.306

5.  Assessing medication adherence and healthcare utilization and cost patterns among hospital-discharged patients with schizoaffective disorder.

Authors:  Sudeep Karve; Michael Markowitz; Dong-Jing Fu; Jean-Pierre Lindenmayer; Chi-Chuan Wang; Sean D Candrilli; Larry Alphs
Journal:  Appl Health Econ Health Policy       Date:  2014-06       Impact factor: 2.561

Review 6.  A critical appraisal of paliperidone long-acting injection in the treatment of schizoaffective disorder.

Authors:  Pierre Chue; James Chue
Journal:  Ther Clin Risk Manag       Date:  2016-01-27       Impact factor: 2.423

7.  Schizoaffective Disorder in an acute psychiatric unit: Profile of users and agreement with Operational Criteria (OPCRIT).

Authors:  Ryola Singh; Ugasvaree Subramaney
Journal:  S Afr J Psychiatr       Date:  2016-05-06       Impact factor: 1.550

8.  Off-label use of sodium valproate for schizophrenia.

Authors:  Einav Horowitz; Lisa Carroll Bergman; Charna Ashkenazy; Irit Moscona-Hurvitz; Haya Grinvald-Fogel; Racheli Magnezi
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

9.  Cognitive Remediation Interventions in Schizoaffective Disorder: A Systematic Review.

Authors:  Ester Lopez-Fernandez; Brisa Sole; Esther Jimenez; Estela Salagre; Anna Gimenez; Andrea Murru; Caterina Del Mar Bonnín; Benedikt Lorenz Amann; Iria Grande; Eduard Vieta; Anabel Martínez-Aran
Journal:  Front Psychiatry       Date:  2018-10-04       Impact factor: 4.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.